Cargando…
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland
BACKGROUND: In July 2021, a new variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the Delta lineage was detected in the United Kingdom (UK), named AY.4.2 or “Delta plus”. By October 2021, the AY.4.2 variant accounted for approximately 10-11% of cases in the UK. AY.4.2 was de...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society of Global Health
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269984/ https://www.ncbi.nlm.nih.gov/pubmed/35802764 http://dx.doi.org/10.7189/jogh.12.05025 |